Akari医疗公共 AKTX 深 沪
等待开盘 12-20 09:30:00 美东时间
0.2601
+0.015
+6.16%
华盛通- 最 高0.265
- 今 开0.2411
- 成交量 182.99万股
- 最 低 0.2356
- 昨 收 0.245
- 总市值 929.59万
- 52周最高 1.73
- 市盈率 静 --
- 换手率 5.12%
- 52周最低 0.2178
- 委 比 97.70%
- 总股本 3573.97万
- 历史最高 2380.00
- 量 比 0.48
- 振 幅 12.00%
- 历史最低 0.2178
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Akari Therapeutics CEO participated in a Virtual Investor "What This Means" segment, discussing the company's novel spliceosome modulating payload, PH1, and its potential in treating tough cancers. The segment highlighted new preclinical data showing therapeutic potential of lead ADC AKTX-101 in hard-to-treat KRAS-mutant pancreatic cancer, with plans for clinical testing by late 2026/early 2027. AKTX-101 targets Trop2 receptor, delivering PH1 pay...
12-18 13:30
Akari Therapeutics Announces $5M Financing Agreement
Akari Therapeutics ( ($AKTX) ) has provided an announcement. Akari Therapeutics...
12-17 23:48
Akari Therapeutics Approves Key Resolutions at Meeting
Akari Therapeutics ( ($AKTX) ) just unveiled an announcement. On December 15, 2...
12-17 06:21
Akari Therapeutics To Issue ~12.6M ADSs And Series G Warrants At $0.3883–$0.4041, Raising Gross Process Of ~$5M
Akari Therapeutics, Plc (NASDAQ:AKTX) (the "Company"), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into definitive agreements for the
12-16 22:31
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
Akari Therapeutics, a biotech company, announced the publication of a new CEO Corner segment highlighting its progress in developing an innovative ADC platform targeting the spliceosome. The company's PH1 payload, designed to disrupt RNA splicing, shows potential as a monotherapy or in combination with checkpoint inhibitors. Its lead candidate, AKTX-101, targeting the Trop2 receptor, is advancing toward clinical trials in Q4 2026. Akari aims to a...
12-04 14:00
Akari Therapeutics Announces Release of the Next CEO Corner Segment
Akari Therapeutics announced the publication of its latest CEO Corner segment, where CEO Abizer Gaslightwala highlights the company's innovation in antibody drug conjugates (ADCs), particularly its novel PH1 payload with a dual mechanism of action. He also discusses Akari's next-generation ADC discovery platform and its mission to develop differentiated therapies for patients. The PH1 payload, a spliceosome modulator, disrupts RNA splicing in can...
11-25 14:00
Akari Therapeutics appoints interim CFO
Akari Therapeutics (AKTX) announced the appointment of Kameel D. Farag as its interim chief financial officer, who joined Akari last month. Farag most recently served as CFO and head of business oper...
11-18 21:52
Akari Therapeutics Appoints Kameel D. Farag As Interim Chief Financial Officer
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the appointment of Kameel D. Farag as its Interim Chief Financial
11-18 21:41
Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Teradata Corp (NYSE:TDC) rose sharply in pre-market trading after the...
11-05 18:09
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
Akari Therapeutics announced the formation of its Scientific Advisory Board (SAB) with Dr. Sara Hurvitz as its inaugural member. Dr. Hurvitz, an internationally recognized oncology expert, specializes in ADCs and targeted therapies for breast cancer. She brings extensive clinical expertise in managing cancers across all stages, particularly in neoadjuvant treatments and immune-based approaches. Akari is developing next-generation spliceosome payl...
10-30 12:35
